BioLife Solutions (NASDAQ:BLFS) Rating Increased to Hold at StockNews.com

BioLife Solutions (NASDAQ:BLFS - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Tuesday.

Other analysts have also recently issued research reports about the company. HC Wainwright raised their price objective on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Benchmark reissued a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, Northland Securities increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, BioLife Solutions has a consensus rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Stock Up 4.3 %

Shares of BLFS stock traded up $0.91 during mid-day trading on Tuesday, hitting $21.90. 596,266 shares of the stock traded hands, compared to its average volume of 373,805. BioLife Solutions has a 52-week low of $14.84 and a 52-week high of $29.55. The stock has a market cap of $1.03 billion, a P/E ratio of -20.66 and a beta of 1.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock's fifty day moving average is $25.04 and its two-hundred day moving average is $25.34.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the business posted ($0.21) EPS. Equities analysts predict that BioLife Solutions will post -0.3 EPS for the current year.

Insider Transactions at BioLife Solutions

In related news, CFO Troy Wichterman sold 4,151 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00. Following the completion of the transaction, the chief financial officer now owns 116,809 shares of the company's stock, valued at $2,920,225. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 1,597 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,925.00. Following the completion of the sale, the executive vice president now directly owns 260,601 shares in the company, valued at approximately $6,515,025. The trade was a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,127 shares of company stock worth $1,676,533 over the last three months. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BLFS. Invesco Ltd. increased its holdings in shares of BioLife Solutions by 1.1% during the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider's stock valued at $84,097,000 after purchasing an additional 36,176 shares in the last quarter. Fred Alger Management LLC grew its position in BioLife Solutions by 1.0% during the fourth quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider's stock valued at $41,386,000 after buying an additional 16,274 shares during the period. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after buying an additional 95,788 shares in the last quarter. Millennium Management LLC raised its position in shares of BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock worth $29,733,000 after acquiring an additional 377,111 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of BioLife Solutions by 4.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider's stock worth $23,028,000 after acquiring an additional 40,416 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.